|
DATE: April 22, 2008
SUBJECT: Web-Based Electronic Data Submission
WEB-BASED ELECTRONIC DATA SUBMISSION
Web-Based Electronic Data Submission is now available for the following RTOG forms:
0614 T1 Radiotherapy Form
0623 TI Radiotherapy Form
Per previous Broadcasts, web-based data submission became MANDATORY as of May 14, 2007 for all forms available for web-entry for all cases enrolled through RTOG. A complete listing of forms available for web data submission is available at http://www.rtog.org/members/webreg.htm
For technical support with web data submission, please email websupport@phila.acr.org.
Web registration is available 24/7. Information and instructions are at https://silver1.phila.acr.org/Clinical_RTOG/pgIndex.html
|
 |
DATE: February 5, 2008
SUBJECT: RTOG 0623, Updated
Updated
RTOG 0623, “A Phase II Trial Of Combined Modality Therapy With Growth Factor Support For Patients With Limited Stage Small Cell Lung Cancer“: Update: The CALGB Co-Chairs were removed from the title page, and a word was corrected in Appendix I, the sample consent.
Sites can access the complete summary of changes at http://www.rtog.org/members/protocols/0623/summary_changes.html
Sites can download a copy of the protocol for IRB review by accessing the RTOG web site at http://www.rtog.org/members/protocols/0623/0623.pdf
NCI policy requires that the "Version Date" on the protocol title page reflect the date the amendment was submitted by RTOG to NCI; for clarity, the broadcast date is provided in parentheses. The "Update Date" indicates that editorial/administrative changes were made to the protocol after NCI approved the amendment. NCI requires that these changes be documented on the protocol title page as an update, not as an amendment. IRB review of an update is not required; however, these changes must be reported to site IRBs.
Please notify your affiliates that are not on e-mail.
To share a comment or ask a question, access the Headquarters Information and Telephone Listing on the RTOG web site, www.rtog.org, under "Member Info", or call 1-800-227-5463, ext. 4189, which provides a menu to reach the Headquarters departments. If you would like to be added or removed from the RTOG broadcast list or wish to update your e-mail address, contact Michelle Buado at mbuado@phila.acr.org
Web registration is available 24/7. Information and instructions available at https://silver1.phila.acr.org/Clinical_RTOG/pgIndex.html
|
|
DATE: January, 15, 2008
SUBJECT: RTOG 0623, Updated
Updated
RTOG 0623, "A Phase II Trial Of Combined Modality Therapy With Growth Factor Support For Patients With Limited Stage Small Cell Lung Cancer": Update: All references to an IND for filgrastim were deleted as this is an IND exempt study.
Sites can access the complete summary of changes at http://www.rtog.org/members/protocols/0623/summary_changes.html
Sites can download a copy of the protocol for IRB review by accessing the RTOG web site at http://www.rtog.org/members/protocols/0623/0623.pdf
NCI policy requires that the "Version Date" on the protocol title page reflect the date the amendment was submitted by RTOG to NCI; for clarity, the broadcast date is provided in parentheses. The "Update Date" indicates that editorial/administrative changes were made to the protocol after NCI approved the amendment. NCI requires that these changes be documented on the protocol title page as an update, not as an amendment. IRB review of an update is not required; however, these changes must be reported to site IRBs.
Please notify your affiliates that are not on e-mail.
To share a comment or ask a question, access the Headquarters Information and Telephone Listing on the RTOG web site, www.rtog.org, under "Member Info", or call 1-800-227-5463, ext. 4189, which provides a menu to reach the Headquarters departments. If you would like to be added or removed from the RTOG broadcast list or wish to update your e-mail address, contact Michelle Buado at mbuado@phila.acr.org
Web registration is available 24/7. Information and instructions available at https://silver1.phila.acr.org/Clinical_RTOG/pgIndex.html
|
|
DATE: January, 8, 2008
SUBJECT: RTOG 0623, Activated
Activated
RTOG 0623, "A Phase II Trial Of Combined Modality Therapy With Growth Factor Support For Patients With Limited Stage Small Cell Lung Cancer"
You may download a copy of the protocol for IRB review by accessing the RTOG web site at http://www.rtog.org/members/protocols/0623/0623.pdf
Forms for this study are available on the RTOG web site at http://www.rtog.org/members/forms/0623/main.html
Note: A Study Agent Shipment Form for this study is available on the RTOG web site next to the protocol.
Regulatory Notes: NCI policy requires that the "Version Date" of the protocol reflect the date that the protocol was submitted by RTOG to NCI; therefore, the version date and the activation date on the protocol title page are not the same. The "Update Date" (the same as the activation date) indicates that minor administrative changes were made to the protocol after NCI approval; these changes are detailed in a summary of changes that can be accessed at http://www.rtog.org/members/protocols/0623/summary_changes.html
Please notify your affiliates who are not on e-mail.
To share a comment or ask a question, access the Headquarters Information and Telephone Listing on the RTOG web site, www.rtog.org, under "Member Info", or call 1-800-227-5463, ext. 4189, which provides a menu to reach the Headquarters departments. If you would like to be added or removed from the RTOG broadcast list or wish to update your e-mail address, contact Michelle Buado at mbuado@phila.acr.org
Web registration is available 24/7. Information and instructions available at https://silver1.phila.acr.org/Clinical_RTOG/pgIndex.html
|
|
 |
|
|
|
